Universiti Teknologi Malaysia Institutional Repository

Rituximab: modes of action, remaining dispute and future perspective

Abulayha, Abdulmunem and Bredan, Amin S. and El-Enshasy, Hesham Ali and Daniels, Ian (2014) Rituximab: modes of action, remaining dispute and future perspective. Future Oncology, 10 (15). pp. 2481-2492. ISSN 1479-6694

Full text not available from this repository.

Official URL: http://dx.doi.org/10.2217/fon.14.146


Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research.

Item Type:Article
Uncontrolled Keywords:mechanism, rituximab
Subjects:R Medicine > RC Internal medicine
Divisions:Chemical Engineering
ID Code:62489
Deposited By: Widya Wahid
Deposited On:15 Jun 2017 01:14
Last Modified:15 Jun 2017 01:14

Repository Staff Only: item control page